Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos (NASDAQ:AIMD) reported Q3 2024 financial results with zero revenue compared to $24,489 in Q3 2023. The company reported a net loss of $3.7M, up from $3.0M in Q3 2023. Operating expenses increased to $3.0M from $2.6M, primarily due to higher R&D investments. Cash position strengthened to $5.2M as of September 30, 2024.
Key developments include securing multi-regional patent assets for AI Nose technology, expanding VELDONA® patent portfolio for coronavirus treatments, and progressing clinical trials for Sjögren's syndrome and HIV-related oral warts. The AI Nose platform achieved 79% accuracy in detecting VOCs in semiconductor factories.
Ainos (NASDAQ:AIMD) has secured exclusive licensing rights for 28 multi-regional patent assets from strategic shareholder Taiwan Carbon Nano Technology (TCNT). The patents cover AI Nose gas sensing technology and a breakthrough nitrogen-oxygen separation technology for medical applications. The new separation technology achieves over 99% purity while using one-third of the energy compared to conventional methods, offering significant cost reduction and environmental benefits.
The patent portfolio spans multiple regions including China, Japan, Korea, Taiwan, Germany, the EU, and the US. The agreement grants Ainos exclusive sales rights for the medical-grade nitrogen-oxygen separation technology, positioning the company for expansion in the advanced medical equipment market.
Ainos (NASDAQ:AIMD) showcased VELDONA®'s clinical progress and market potential in a Water Tower Research podcast. VELDONA®, an oral low-dose interferon-α therapeutic, has undergone 68 clinical studies across 16 indications with 6,000 participants, demonstrating strong safety. The company is focusing on two human studies in Taiwan: oral warts in HIV+ patients and Sjogren's syndrome. Previous trials showed over 75% reduction in wart-affected areas. In animal health, Ainos is exploring VELDONA®'s potential for feline chronic gingivostomatitis. Key milestones include completing the FCGS study by March 2025, filing FDA IND in 2025, completing Taiwan human studies in early 2026, and exploring global licensing opportunities.
Ainos, Inc. (NASDAQ:AIMD) has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial on VELDONA®, a low-dose oral interferon formulation for treating oral warts in HIV-positive patients. The trial, involving 40 participants, will evaluate VELDONA®'s efficacy in combination with antiretroviral therapy. VELDONA® has received orphan drug designation from the FDA, highlighting its potential in addressing an unmet medical need.
The next step is obtaining approval from the Taiwan Food and Drug Administration (TFDA). The application was submitted on August 28, 2024. The Site Initiation Visit is expected in November 2024, with patient enrollment lasting one year. The study is anticipated to conclude by July 2026.
Ainos, Inc. (NASDAQ:AIMD) has been featured in a Water Tower Research report highlighting its upcoming VELDONA® clinical study for Sjogren's syndrome, set to begin in December 2024 in Taiwan. The study will enroll 24 patients to assess VELDONA®'s effectiveness in reducing dryness symptoms over 24-48 weeks. Key points include:
1. Taiwan FDA approval expected by November 2024
2. Trial projected to complete by January 2026
3. Primary endpoint: improvement of saliva secretion and dryness symptoms
4. Secondary endpoints: ESSPRI, ESSDAI, VAS, and salivary gland function
5. Sjogren's syndrome affects up to 1% of the global population
6. Previous U.S. Phase 3 data showed significant improvements
This study follows Ainos' capital-efficient strategy of conducting clinical trials in Taiwan, with a prior VELDONA study for oral warts in HIV+ patients planned for November 2024.
Ainos (NASDAQ:AIMD) has announced plans to conduct a Taiwan clinical study for VELDONA in treating Sjögren's syndrome, a rare autoimmune disease. The study, to be conducted at Taipei Medical University-Shuang Ho Hospital, aims to recruit 24 patients who will take three sublingual VELDONA tablets daily for 24-48 weeks. The primary objective is to evaluate VELDONA's efficacy in improving saliva secretion and dryness symptoms.
The company has previously conducted eight clinical trials in the U.S., including three Phase 3 studies that showed positive benefits in increasing unstimulated whole saliva secretion without significant adverse effects. Ainos expects to complete all regulatory approvals for the Taiwan study by November 2024, with patient enrollment lasting approximately six months. The study is projected to conclude in January 2026.
Ainos, Inc. (NASDAQ:AIMD) has announced a new clinical trial for VELDONA®, its low-dose oral interferon-alpha formulation, to treat oral warts in HIV+ patients on antiretroviral therapy. Water Tower Research has issued a report highlighting key aspects of this upcoming trial:
1. The single-site, double-blind study will commence at the National Taiwan University Hospital by November 2024.
2. The trial will enroll 40 subjects, randomized 3:1 to VELDONA® or placebo.
3. The primary endpoint is a 75% reduction in oral wart surface area over 24 weeks.
4. VELDONA® has received Orphan Drug Designation from the FDA for this indication.
5. The study aligns with Ainos' capital-efficient strategy, as clinical studies in Taiwan are less costly than in the U.S.
6. There are currently no approved therapeutics for oral warts, which affect approximately 49,000 HIV+ patients in the U.S.
Ainos (NASDAQ:AIMD) has announced plans to initiate a clinical study for VELDONA, a low-dose oral interferon-alpha formulation, as a potential treatment for oral warts in HIV-positive patients. The study will be conducted at National Taiwan University Hospital, involving 40 participants in a double-blind trial lasting 24 weeks. VELDONA has received Orphan Drug Designation from the U.S. FDA for this indication.
The study aims to evaluate the efficacy of VELDONA in reducing oral wart surface area, with a successful response defined as a 75% or greater reduction. Previous U.S. trials involving 77 HIV-positive patients showed significant reductions in oral wart surface area, with decreases of over 75% and up to 99% in some cases. The study is expected to begin in November 2024 and conclude in July 2026.
Ainos (NASDAQ:AIMD) has secured a Taiwan invention patent for VELDONA®, its breakthrough formulation for coronavirus treatment and prevention. The company has also filed for global patent protection under the Patent Cooperation Treaty (PCT). VELDONA® utilizes an advanced oral rapid-dissolving tablet technology that enhances immune system function and reduces the risk of coronavirus infections.
Key highlights:
- VELDONA® shows potential in activating the immune system against various coronavirus variants and preventing new infections
- The technology may extend to other viral diseases, including Hepatitis B, HIV, and various animal viruses
- Ainos believes VELDONA® could become a competitive, comprehensive antiviral therapy due to its high efficacy, safety, and low side effects
Ainos (NASDAQ: AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and VELDONA low-dose interferon therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person at the Lotte New York Palace Hotel and virtually on September 9-10, 2024.
Key highlights:
- Ainos will conduct one-on-one meetings during the conference
- Mr. Jack Lu, Director of Corporate Development, will deliver a live presentation on September 10, 2024, at 4 p.m.
- The company invites shareholders and interested parties to learn about their journey towards becoming 'AI's nose' capable of digitizing smell
- Interested attendees can register for the conference through the HCW Events website